Extranodal Lymphoma — Trials

Extranodal Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 18
Ph III recruiting: 1
Growth YoY: —
Industry share: 13%
Top sponsor: Ruijin Hospital
Termination share: 32.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (43)

clinicaltrialsPublishedShowing 1–19 of 19 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07791615	A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma	not yet recruiting	Phase 2	20	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	0	Aug 28, 2026	clinicaltrials
NCT07768943	GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma	not yet recruiting	Phase 2	620	Fudan UniversityOTHER	1	Aug 17, 2026